Characteristics of patients with AML who received IC after HMA and VEN stratified by prior response to HMA/VEN
| . | HMA/VEN response . | P . | |
|---|---|---|---|
| Refractory . | Relapse∗ . | ||
| No. of patients, n (%) | 32 (70) | 14 (30) | |
| Sex, n (%) | |||
| Female | 12 (38) | 8 (57) | .33 |
| Male | 20 (63) | 6 (43) | |
| Age, median (interquartile range) | 65 (53-68) | 64 (41-68) | .41 |
| Diagnosis, n (%) | |||
| AML | 26 (81) | 11 (79) | 1 |
| MDS/AML | 6 (19) | 3 (21) | |
| AML classification, n (%) | |||
| Recurrent genetic abnormality | 7 (22) | 6 (43) | .63 |
| TP53 (mutated or lost) | 6 (19) | 2 (14) | |
| Myelodysplasia-related gene mutation | 11 (34) | 3 (21) | |
| Myelodysplasia-related cytogenetic abnormality | 3 (9) | 2 (14) | |
| Not otherwise specified | 5 (16) | 1 (7) | |
| AML qualifier, n (%) | |||
| Therapy related | 4 (13) | 3 (21) | .83 |
| Prior MDS or MDS/MPN | 14 (44) | 5 (36) | |
| Germ line predisposition | 1 (3) | 0 (0) | |
| None | 13 (41) | 6 (43) | |
| ELN 2022 risk classification, n (%) | |||
| Favorable | 1 (3) | 3 (21) | .20 |
| Intermediate | 7 (22) | 3 (21) | |
| Adverse | 23 (72) | 8 (57) | |
| Unknown | 1 (3) | 0 (0) | |
| VEN combination, n (%) | |||
| AZA | 24 (75) | 13 (93) | .24 |
| Decitabine | 8 (25) | 1 (7) | |
| HMA/VEN line of treatment, n (%) | |||
| 1 | 19 (59) | 5 (36) | .20 |
| 2+ | 13 (41) | 9 (64) | |
| Prior HMA, n (%) | 7 (22) | 2 (14) | .7 |
| Prior IC, n (%) | 13 (41) | 8 (57) | .35 |
| Prior Transplant, n (%) | 4 (29) | 11 (34) | 1 |
| HMA/VEN cycles, median (interquartile range) | 2 (1-2) | 4.5 (2-6) | .01 |
| HMA/VEN response, n (%) | |||
| CR | 0 (0) | 6 (43) | N/A |
| CRi | 0 (0) | 5 (36) | |
| MLFS | 0 (0) | 3 (21) | |
| PR | 1 (3) | 0 (0) | |
| NR | 31 (97) | 0 (0) | |
| . | HMA/VEN response . | P . | |
|---|---|---|---|
| Refractory . | Relapse∗ . | ||
| No. of patients, n (%) | 32 (70) | 14 (30) | |
| Sex, n (%) | |||
| Female | 12 (38) | 8 (57) | .33 |
| Male | 20 (63) | 6 (43) | |
| Age, median (interquartile range) | 65 (53-68) | 64 (41-68) | .41 |
| Diagnosis, n (%) | |||
| AML | 26 (81) | 11 (79) | 1 |
| MDS/AML | 6 (19) | 3 (21) | |
| AML classification, n (%) | |||
| Recurrent genetic abnormality | 7 (22) | 6 (43) | .63 |
| TP53 (mutated or lost) | 6 (19) | 2 (14) | |
| Myelodysplasia-related gene mutation | 11 (34) | 3 (21) | |
| Myelodysplasia-related cytogenetic abnormality | 3 (9) | 2 (14) | |
| Not otherwise specified | 5 (16) | 1 (7) | |
| AML qualifier, n (%) | |||
| Therapy related | 4 (13) | 3 (21) | .83 |
| Prior MDS or MDS/MPN | 14 (44) | 5 (36) | |
| Germ line predisposition | 1 (3) | 0 (0) | |
| None | 13 (41) | 6 (43) | |
| ELN 2022 risk classification, n (%) | |||
| Favorable | 1 (3) | 3 (21) | .20 |
| Intermediate | 7 (22) | 3 (21) | |
| Adverse | 23 (72) | 8 (57) | |
| Unknown | 1 (3) | 0 (0) | |
| VEN combination, n (%) | |||
| AZA | 24 (75) | 13 (93) | .24 |
| Decitabine | 8 (25) | 1 (7) | |
| HMA/VEN line of treatment, n (%) | |||
| 1 | 19 (59) | 5 (36) | .20 |
| 2+ | 13 (41) | 9 (64) | |
| Prior HMA, n (%) | 7 (22) | 2 (14) | .7 |
| Prior IC, n (%) | 13 (41) | 8 (57) | .35 |
| Prior Transplant, n (%) | 4 (29) | 11 (34) | 1 |
| HMA/VEN cycles, median (interquartile range) | 2 (1-2) | 4.5 (2-6) | .01 |
| HMA/VEN response, n (%) | |||
| CR | 0 (0) | 6 (43) | N/A |
| CRi | 0 (0) | 5 (36) | |
| MLFS | 0 (0) | 3 (21) | |
| PR | 1 (3) | 0 (0) | |
| NR | 31 (97) | 0 (0) | |
Relapsed AML after previously documented CR/CRi/MLFS with HMA/VEN for AML.